| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 07/13/2005 | EP1551841A1 Pyrazolopyrimidines as kinase inhibitors |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551834A1 Substituted quinazolinone compounds |
| 07/13/2005 | EP1551814A1 Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists |
| 07/13/2005 | EP1551810A1 Diaryl-substituted cyclic urea derivatives having an mch-modulatory effect |
| 07/13/2005 | EP1551803A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 07/13/2005 | EP1551511A2 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 07/13/2005 | EP1551443A2 Proteins involved in the regulation of energy homeostasis |
| 07/13/2005 | EP1551440A2 Uses of human zven proteins and polynucleotides |
| 07/13/2005 | EP1551436A2 Formulations for amylin agonist peptides |
| 07/13/2005 | EP1551434A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/13/2005 | EP1551432A1 Argyrolobium roseum plant extracts for treating diabetes |
| 07/13/2005 | EP1551431A2 Purified amylase inhibitor and novel process for obtaining the same |
| 07/13/2005 | EP1551416A2 Method for treating erectile dysfunction and increasing libido in men |
| 07/13/2005 | EP1551356A2 Pravastatin pharmaceutical formulations and methods of their use |
| 07/13/2005 | EP1315695B1 Benzene tricarboxylic acid amides as insulin receptor activators |
| 07/13/2005 | EP1207860A4 Controlled release pellet formulation |
| 07/13/2005 | EP1161415B1 N-cyanomethylamides as protease inhibitors |
| 07/13/2005 | EP1144364B1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/13/2005 | EP1119363B1 Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug |
| 07/13/2005 | EP1001976B1 Peptides having potassium channel opener activity |
| 07/13/2005 | CN1639343A Method for detection of leptin receptor ligands |
| 07/13/2005 | CN1639317A Probiotic lactobacillus salivarius strains |
| 07/13/2005 | CN1639188A Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 07/13/2005 | CN1639180A Aryl 5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same |
| 07/13/2005 | CN1639167A Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity |
| 07/13/2005 | CN1639165A Purine derivatives as kinase inhibitors |
| 07/13/2005 | CN1639162A Pyrido(2, 1-a)isoquinoline derivatives as DPP-IV inhibitors |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639158A Thiazole derivatives as NPY receptor antagonists |
| 07/13/2005 | CN1639153A Indolylmaleimide derivatives |
| 07/13/2005 | CN1639152A Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors |
| 07/13/2005 | CN1639140A Benzothiazepine derivatives for the treatment of hyperlipidemia |
| 07/13/2005 | CN1639139A 5-phenylthiazole derivatives and use as PI3 kinase inhibitors |
| 07/13/2005 | CN1639137A Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxadiazol-2-ones, the production thereof and their use in medicaments |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639126A Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639120A Indolamid derivatives which possess glycogenphosphorylase inhibitory activity |
| 07/13/2005 | CN1638823A N-{5-[4-(4-methyl-piperazino-methyl)--benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 07/13/2005 | CN1638803A Tablets quickly disintegrating in oral cavity |
| 07/13/2005 | CN1638801A Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638790A Compositions and methods for modulating connexin hemichannels |
| 07/13/2005 | CN1638779A Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
| 07/13/2005 | CN1638778A Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 07/13/2005 | CN1638768A Thiazole and oxazole derivatives that modulate PPAR activity |
| 07/13/2005 | CN1638766A Use of substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazole-2-one for producing medicaments that inhibit pancreatic lipase |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638758A Stimulation of CPT-1 as a means to reduce weight |
| 07/13/2005 | CN1638757A 组织蛋白酶半胱氨酸蛋白酶抑制剂 Cathepsin cystatin |
| 07/13/2005 | CN1638755A Body temperature elevating agents |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638750A Pharmaceutical compositions for oral use, containing, in combination, metformin and glyclazide |
| 07/13/2005 | CN1638747A Sustained release pharmaceutical composition |
| 07/13/2005 | CN1638650A Composition improving age-related physiological deficits and increasing longevity |
| 07/13/2005 | CN1637137A Method of inducing stem cell to differentiate to insulin-like cell and its application |
| 07/13/2005 | CN1637018A Novel effectors of dipeptidyl peptidase IV |
| 07/13/2005 | CN1636993A Process for producing novel form of paroxetine hydrochloride anhydrate |
| 07/13/2005 | CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/13/2005 | CN1636980A 二肽腈组织蛋白酶k抑制剂 Dipeptide nitrile cathepsin inhibitors k |
| 07/13/2005 | CN1636977A 1, 3-disubstituted pyrrolidines as alpha-2-adrenoceptor antagonists |
| 07/13/2005 | CN1636593A Novel effectors of dipeptidyl peptidase IV |
| 07/13/2005 | CN1636588A Red yeast prepn containing active components of glossy ganoderma and its prepn process |
| 07/13/2005 | CN1636579A Hypoglycemic Chinese medicine prepn and its production process |
| 07/13/2005 | CN1636574A Lipase inhibiting polymers |
| 07/13/2005 | CN1636572A Compositions and methods for treatment of mitochondrial diseases |
| 07/13/2005 | CN1636566A Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 07/13/2005 | CN1636563A 噻唑衍生物 Thiazole derivatives |
| 07/13/2005 | CN1636557A Simple production process for zinc citrate, zinc lactate, ferrous citrate and ferrous lactate |
| 07/13/2005 | CN1636553A Volatile proof solid preparation and producing method thereof |
| 07/13/2005 | CN1210285C Remedies |
| 07/13/2005 | CN1210273C Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/13/2005 | CN1210270C Novel use of phenylheteroalkylamine derivatives |
| 07/13/2005 | CN1210266C Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl (methysulfonyl)amino]pyrimidin-5-yl]-(3R5S)-3,5-dihydroxyhept-6-enojc acid |
| 07/13/2005 | CN1210263C N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 07/13/2005 | CN1210262C Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol |
| 07/13/2005 | CN1210261C Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5HT1A receptor activity |
| 07/13/2005 | CN1210260C Crystalline forms of fluvastatin sodium |
| 07/13/2005 | CN1210258C Glyburide composition |
| 07/13/2005 | CN1210251C Substituted nor bornylamion derivatives, method for production thereof, use thereof and medicaments containing said compounds |
| 07/13/2005 | CN1210066C Cloning pigs using donor nuclei from differentiated cells |
| 07/13/2005 | CN1210058C Stable concentrated insulin preparations for pulmonary delivery |
| 07/13/2005 | CN1210057C Blood lipid capsule and its preparing method |
| 07/13/2005 | CN1210049C Chinese medicine composition for treating diabetes and preparing method thereof |
| 07/13/2005 | CN1210045C Medicine for curing diabetes |
| 07/13/2005 | CN1210039C Total sanchinoside and ferulic acid composition for treating cardio-cerebral vascular disease and diabetes and its use |
| 07/12/2005 | US6916961 Compound for use in the prevention and treatment of respiratory and nervous system disorders |
| 07/12/2005 | US6916922 Acylating a cyclopentaindolemethylamine and cyclizing and reducing the product |
| 07/12/2005 | US6916857 Hydrogel-forming system with hydrophobic and hydrophilic components |
| 07/12/2005 | US6916848 Compounds for the treatment of metabolic disorders |
| 07/12/2005 | US6916838 1-benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/12/2005 | US6916834 Preparations and use of an Ah receptor ligand, 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 07/12/2005 | US6916810 αν integrin receptor antagonists |
| 07/12/2005 | US6916809 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 07/12/2005 | US6916808 2-thio-4h-3, 1-benzoxazin-4-one derivatives for use as enzyme inhibitors |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916804 Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| 07/12/2005 | US6916798 Inhibitors of glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase; for treatment and prevention of diabetes and Alzheimer's disease |